A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy
- 1 March 2000
- Vol. 9 (2) , 80-87
- https://doi.org/10.1053/seiz.2000.0380
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsyPublished by Elsevier ,1998
- The new generation of antiepileptic drugs: advantages and disadvantagesBritish Journal of Clinical Pharmacology, 1996
- The Clinical Pharmacokinetics of the Newer Antiepileptic DrugsClinical Pharmacokinetics, 1996
- Efficacy and tolerability study of ucb L059 in patients with refractory epilepsyJournal of Epilepsy, 1996
- The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranesEuropean Journal of Pharmacology, 1995
- Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsyEpilepsy Research, 1995
- Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and ratsEuropean Journal of Pharmacology, 1993
- Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic SeizuresNew England Journal of Medicine, 1985
- Proposal for Revised Clinical and Electroencephalographic Classification of Epileptic SeizuresEpilepsia, 1981